Public sector genetic testing laboratories in Europe are ignoring intellectual property rights and deterring investment in the biomarkers that underpin personalised medicine
When the US Congress reconvenes next month, the Patent Reform Act of 2011 - the first major overhaul of the American patent system since 1952 - will be top of its agenda.
This is the UK’s largest ever investment in translational health research. The 31 separate awards include funding for four new Biomedical Research Units, specialising in dementia research.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.